|Location|| Building 13 |
Via Adamello 16, Milano
Andrea Castiglioni developed a passion for cancer research when he started to learn about the delicate equilibrium between oncogenes and oncosuppressors and the mechanisms that drive tumorigenesis. During his initial studies, under the mentorship of Prof. Ciro Isidoro, Head of the Molecular Pathology Lab in Novara, he focused his research on unveiling the role of autophagy, a homeostatic process deregulated in many tumors that has been linked to poor prognosis, tumor recurrence and chemotherapy resistance. During this period, he expanded his knowledge on the unbalanced interactions that occur in many cancer types due to oncosuppressor deletion. In particular, he worked on the identification of new oncogenic proteins targeted by the oncosuppressor PTEN, to better understand the mechanisms that could induce drug resistance and uncontrolled proliferation of tumor cells. Andrea currently holds the position of PhD student at the European School of Molecular Medicine (SEMM) in Prof. Pier Paolo Di Fiore’s group. He has been awarded a FIRC-AIRC Fellowship for his project focused on the validation of a novel prostate cancer stem cell (PCSC) biomarker that could be used to develop new clinical tools for the clinical management and treatment of prostate cancer patients. With enthusiasm and devotion, he aspires to develop targeted therapies against PCSCs through the deconvolution of PCSC heterogeneity by single cell sequencing for the identification of novel therapeutic targets.